乙型肝炎相关混合冷球蛋白血症:疾病进展的潜在生物标志物
该研究回顾性分析44例HBV阳性患者(22例伴混合冷球蛋白、22例不伴)及20例健康献血者的血清IgG亚类、类风湿因子和游离轻链,发现HBV阳性者与健康者间IgG亚类分布和RF同型存在显著差异,FLCs显著升高,但伴或不伴冷球蛋白的HBV患者间FLCs无显著差异。结论提示HBV触发的免疫炎症反应可通过特定生物标志物谱监测。
要点
- HBV阳性患者与健康献血者间血清IgG亚类分布和RF同型存在显著差异。
- HBV阳性患者FLCs较健康献血者显著升高,但伴与不伴冷球蛋白者间无显著差异。
- 特定生物标志物谱或可用于监测HBV触发的免疫炎症反应。
核心结论
- HBV触发的免疫炎症反应可通过特定生物标志物谱(IgG亚类、RF同型、FLCs)进行监测,为精准医学提供新视角。
研究设计与样本
- 回顾性分析44例HBV阳性患者的临床数据,按是否伴混合冷球蛋白分为两组(各22例),并以20例健康献血者血清作为阴性对照。
- 检测血清IgG亚类、RF(IgM、IgG和IgA型)及游离轻链(FLCs)。
主要发现
- 健康献血者与HBV阳性患者间血清IgG亚类分布存在显著差异,RF同型亦不同。
- HBV阳性患者FLCs较健康献血者显著升高,但伴与不伴混合冷球蛋白的HBV患者间FLCs无显著差异。
临床怎么用
- IgG亚类、RF同型和FLCs或可作为监测HBV相关免疫炎症反应的候选生物标志物。
- 对HBV阳性患者可考虑检测上述指标以辅助临床评估,但需进一步验证。
局限性
- 回顾性研究,样本量较小(44例HBV阳性患者和20例健康献血者)。
- 伴与不伴混合冷球蛋白的HBV患者间FLCs无显著差异,标志物区分能力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The biomarkers of an immunological dysregulation due to a chronic HBV infection are indeed understudied. If untreated, this condition may evolve into liver impairment co-occurring with extrahepatic involvements. Here, we aim to identify a new panel of biomarkers [including immunoglobulin G (IgG) subclasses, RF, and Free Light Chains (FLCs)] that may be useful and reliable for clinical evaluation of HBV-related cryoglobulinemia. METHODS: We retrospectively analysed clinical data from 44 HBV-positive patients. The patients were stratified (according to the presence/absence of mixed cryoglobulinemia) into two groups: 22 with cryoglobulins (CGs) and 22 without CGs. Samples from 20 healthy blood donors (HDs) were used as negative controls. Serum samples were tested for IgG subclasses, RF (-IgM, -IgG, and -IgA type), and FLCs. RESULTS: We detected a strikingly different distribution of serum IgG subclasses between HDs and HBV-positive patients, together with different RF isotypes; in addition, FLCs were significantly increased in HBV-positive patients compared with HDs, while no significant difference was shown between HBV-positive patients with/without mixed cryoglobulinemia. CONCLUSION: The immune-inflammatory response triggered by HBV may be monitored by a peculiar profile of biomarkers. Our results open a new perspective in the precision medicine era; in these challenging times, they could also be employed to monitor the clinical course of those COVID-19 patients who are at high risk of HBV reactivation due to liver impairment and/or immunosuppressive therapies.
引用
- Pocino K, Napodano C, Gragnani L, et al. Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression. Rheumatology (Oxford). 2021. PMID: 33590837. doi:10.1093/rheumatology/keab157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。